2024
Trends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effects
2023
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacy
2021
“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”
Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML. “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”. BMC Cancer 2021, 21: 352. PMID: 33794808, PMCID: PMC8015735, DOI: 10.1186/s12885-021-08084-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorExerciseFemaleHumansLung NeoplasmsMaleNeoplasm StagingPilot ProjectsQuality of LifeConceptsNon-small cell lung cancerAdvanced-stage lung cancerStage lung cancerUsual carePhysical activityIntervention groupQuality of lifeLung cancerEligible patientsStage III/IV non-small cell lung cancerLow baseline physical activityHome-based physical activityAdvanced stage diseaseSoluble PD-1Stage IV adenocarcinomaBaseline physical activityMinority of patientsCell lung cancerPatient-reported outcomesEffects of exerciseRole functioning domainsLung cancer biologyAspects of QoL.Mobile health interventionsCancer biomarkers
2020
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDeathHumansImmune Checkpoint InhibitorsLung NeoplasmsRetrospective StudiesConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patterns
2013
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer
Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, Decker RH, Hess JA, Chiang VL, Contessa JN. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer. Clinical Cancer Research 2013, 19: 5523-5532. PMID: 23897899, DOI: 10.1158/1078-0432.ccr-13-0836.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGenotypeHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsRadiation ToleranceReceptor Protein-Tyrosine KinasesRecurrenceTranslocation, GeneticTumor BurdenConceptsNon-small cell lung cancerCell lung cancerEML4-ALK translocationGamma knife treatmentLocal controlTumor genotypeLung cancerEGFR mutationsCox proportional hazards modelDistant brain controlDistant brain recurrenceGamma knife radiotherapyEGFR kinase domain mutationsSuperior local controlField local controlKRAS mutation statusProportional hazards modelKinase domain mutationsEGF receptorMetastasis sizeBrain recurrenceBrain metastasesField recurrenceClinical outcomesIndependent predictors